Mursla Bio

Mursla Bio is a diagnostics company developing blood-based tests for early cancer detection using extracellular vesicle biology.

Its platform isolates organ-specific extracellular vesicles from blood and applies multi-omics profiling and machine learning to identify disease biomarkers without tissue biopsy.

Its lead product targets early detection of hepatocellular carcinoma in high-risk cirrhotic patients, demonstrating 86% early-stage sensitivity at 88% specificity in clinical study.